TG Therapeutics Initiates Phase 2 Trial for Briumvi
TG Therapeutics announced the initiation of a Phase 2 clinical trial evaluating Briumvi, in adults with treatment-resistant schizophrenia. The Phase 2 study is an open-label trial designed to evaluate the efficacy and safety of Briumvi in approximately 60 adults with schizophrenia who continue to experience significant symptoms despite receiving standard-of-care antipsychotic treatment.
